Quick Answer
Gossamer Bio, Inc. reported Total Assets of $172.25 million for the year ending 2025.
- Gossamer Bio, Inc. showed a decrease of -45.4% in Total Assets from 2024 to 2025.
- This data is from Gossamer Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $515.95 million | Q2 2019: $507.17 million | Q3 2019: $469.75 million | Q1 2020: $371.48 million | Q2 2020: $625.08 million | Q3 2020: $584.18 million | Q1 2021: $482.47 million | Q2 2021: $432.51 million | Q3 2021: $387.04 million | Q1 2022: $294.68 million | Q2 2022: $245.84 million | Q3 2022: $323.54 million | Q1 2023: $219.91 million | Q2 2023: $181.75 million | Q3 2023: $347.93 million | Q1 2024: $259.36 million | Q2 2024: $373.45 million | Q3 2024: $350.88 million | Q1 2025: $280.59 million | Q2 2025: $240.93 million | Q3 2025: $208.82 million.
- Over the full 8 years of available data (2018 to 2025), Gossamer Bio, Inc.'s Total Assets has declined by 28.1%.
- Historical annual values: Fiscal year 2025: $172.25 million | Fiscal year 2024: $315.29 million | Fiscal year 2023: $311.92 million | Fiscal year 2022: $272.45 million | Fiscal year 2021: $343.66 million | Fiscal year 2020: $539.43 million | Fiscal year 2019: $426.60 million | Fiscal year 2018: $239.42 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: